Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities
Disclosed herein are IL-4 cytokine compositions with enhanced biological activity having increased selectivity for IL-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (IL-4) muteins. The disclosed methods encompass administering an IL-4 to treat neoplastic diseases, autoimmune diseases, infectious diseases or for expanding a hematopoietic cell population.
1. A method for selectively manipulating a cellular response in a target cell to a ligand recognized by two or more shared receptor polypeptides, the method comprising providing a mutein ligand,
wherein the mutein ligand binds one of the two or more shared receptor polypeptides with at least 10-fold higher affinity than the ligand and thereby selectively manipulating the cellular response, wherein one of the shared receptor polypeptides is common γ chain (γc) or interleukin-13 receptor alpha 1 (IL-13Rα1) and
wherein the mutein ligand comprises an IL-4 mutein comprising amino acid substitutions at positions 117, 118, 121, 122, 124, 125, 128 and 129, the amino acid amino acid numbering being in accordance with wild-type human IL-4.
2. The method of claim 1 , wherein the mutein ligand binds two of the two or more shared receptor polypeptides with higher affinity than the ligand and thereby selectively manipulating the cellular response.
3. The method of claim 1 , wherein the mutein ligand binds one of the two or more shared receptor polypeptides with higher affinity and another one of the two or more shared receptor polypeptides with lower affinity than the ligand and thereby selectively manipulating the cellular response.
4. The method of claim 1 wherein the two or more shared receptor polypeptides are not equally present on the target cell surface.
5. The method of claim 4 wherein the shared receptor bound by the mutein ligand is present at lower levels on the target cell surface than the shared receptor not bound by the mutein ligand.
6. The method of claim 4 wherein the shared receptor bound by the mutein ligand is present at higher levels on the target cell surface than the shared receptor not bound by the mutein ligand.
7. The method of claim 1 wherein the shared receptor not bound by the mutein ligand has reduced accessibility to the mutein ligand.
8. The method of claim 7 wherein accessibility to the shared receptor not bound by the mutein ligand is reduced by providing reagents that interfere with the accessibility of the shared receptor not bound by the mutein ligand.
9. The method of claim 8 wherein the reagent is an antibody that recognizes the shared receptor not bound by the mutein ligand.
10. The method of claim 1 wherein the IL-4 mutein comprises the amino acid substitutions 117R, 118V, 121Q, 122S, 124W, 125F, 128G, and 129A.
11. The method of claim 3 wherein the lower affinity is at least 5-fold.